Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Baxter
Teva
Cipla
US Army
Citi
Express Scripts
Farmers Insurance
Queensland Health
Fuji

Generated: August 21, 2017

DrugPatentWatch Database Preview

FLONASE SENSIMIST ALLERGY RELIEF Drug Profile

« Back to Dashboard

Which patents cover Flonase Sensimist Allergy Relief, and when can generic versions of Flonase Sensimist Allergy Relief launch?

Flonase Sensimist Allergy Relief is a drug marketed by Glaxosmithkline Cons and is included in one NDA. There are eight patents protecting this drug.

This drug has two hundred and sixty patent family members in forty-one countries.

The generic ingredient in FLONASE SENSIMIST ALLERGY RELIEF is fluticasone furoate. There are twenty-four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.

Summary for Tradename: FLONASE SENSIMIST ALLERGY RELIEF

Patents:8
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Clinical Trials: see list2,667
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:FLONASE SENSIMIST ALLERGY RELIEF at DailyMed

Pharmacology for Tradename: FLONASE SENSIMIST ALLERGY RELIEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons
FLONASE SENSIMIST ALLERGY RELIEF
fluticasone furoate
SPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Cons
FLONASE SENSIMIST ALLERGY RELIEF
fluticasone furoate
SPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Cons
FLONASE SENSIMIST ALLERGY RELIEF
fluticasone furoate
SPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Cons
FLONASE SENSIMIST ALLERGY RELIEF
fluticasone furoate
SPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► SubscribeYY ► Subscribe
Glaxosmithkline Cons
FLONASE SENSIMIST ALLERGY RELIEF
fluticasone furoate
SPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: FLONASE SENSIMIST ALLERGY RELIEF

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,144,845Compounds useful in the manufacture of an anti-inflammatory androstane derivative► Subscribe
7,629,335Anti-inflammatory androstane derivative► Subscribe
6,878,698 Anti-inflammatory androstane derivatives► Subscribe
7,125,985Compounds useful in the manufacture of an anti-inflammatory androstane derivative► Subscribe
6,537,983 Anti-inflammatory androstane derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FLONASE SENSIMIST ALLERGY RELIEF

Country Document Number Estimated Expiration
Germany60308997► Subscribe
Norway20075156► Subscribe
Czech Republic20030353► Subscribe
New Zealand535873► Subscribe
Portugal1305329► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FLONASE SENSIMIST ALLERGY RELIEF

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
12/2008Austria► SubscribePRODUCT NAME: FLUTICASON FUROAT UND DESSEN SOLVATE
C0014France► SubscribePRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
1305329/01Switzerland► SubscribePRODUCT NAME: FLUTICASON FUROAT; REGISTRATION NUMBER/DATE: SWISSMEDIC 57968 19.12.2007
429Luxembourg► Subscribe91429, EXPIRES: 20230111
C/GB08/026United Kingdom► SubscribePRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Farmers Insurance
Fish and Richardson
Cipla
US Army
Chubb
Mallinckrodt
Deloitte
Daiichi Sankyo
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot